$1.44
2.04% today
Nasdaq, Aug 12, 04:44 pm CET
ISIN
US09073Q1058
Symbol
SCNI

BiondVax Pharmaceuticals Ltd. Sponsored ADR Stock price

$1.47
-0.85 36.50% 1M
-1.85 55.72% 6M
-1.88 56.05% YTD
-2.29 60.90% 1Y
-120.53 98.80% 3Y
-3,598.53 99.96% 5Y
-397.53 99.63% 10Y
-397.53 99.63% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.05 3.29%
ISIN
US09073Q1058
Symbol
SCNI
Industry

Key metrics

Basic
Market capitalization
$1.3m
Enterprise Value
$-400.0k
Net debt
positive
Cash
$2.0m
Shares outstanding
3.4b
Valuation (TTM | estimate)
P/E
- | -
P/S
2.0 | -
EV/Sales
negative | -
EV/FCF
0.1
P/B
0.1
Financial Health
Equity Ratio
74.2%
Return on Equity
48.1%
ROCE
-90.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$660.0k | -
EBITDA
$-8.9m | -
EBIT
$-10.6m | -
Net Income
$2.6m | -
Free Cash Flow
$-6.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
2.9% | -
EBIT
-8.9% | -
Net Income
140.6% | -
Free Cash Flow
36.6%
Margin (TTM | estimate)
Gross
-88.2%
EBITDA
-1,355.2% | -
EBIT
-1,605.8%
Net
400.8% | -
Free Cash Flow
-964.6%
More
EPS
$0.0
FCF per Share
$0.0
Short interest
2.9%
Employees
31
Rev per Employee
$20.0k
Show more

Is BiondVax Pharmaceuticals Ltd. Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

BiondVax Pharmaceuticals Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a BiondVax Pharmaceuticals Ltd. Sponsored ADR forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a BiondVax Pharmaceuticals Ltd. Sponsored ADR forecast:

Buy
86%
Hold
14%

Financial data from BiondVax Pharmaceuticals Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.66 0.66
-
100%
- Direct Costs 1.24 1.24
-
188%
-0.58 -0.58
-
-88%
- Selling and Administrative Expenses 3.01 3.01
34% 34%
456%
- Research and Development Expense 7.10 7.10
37% 37%
1,076%
-8.92 -8.92
3% 3%
-1,352%
- Depreciation and Amortization 1.65 1.65
224% 224%
250%
EBIT (Operating Income) EBIT -11 -11
9% 9%
-1,601%
Net Profit 2.64 2.64
141% 141%
400%

In millions USD.

Don't miss a Thing! We will send you all news about BiondVax Pharmaceuticals Ltd. Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BiondVax Pharmaceuticals Ltd. Sponsored ADR Stock News

Neutral
PRNewsWire
14 days ago
New data builds on award-winning research and confirms efficacy and safety of PC111 across in-vitro, ex-vivo, and in-vivo humanized models JERUSALEM , July 29, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company developing inflammation and immunology (I&I) biological products and providing boutique CDMO services, announced the publication of a new pee...
Neutral
PRNewsWire
2 months ago
CEO Amir Reichman to meet investors, pharma partners, and CDMO clients at global biotech conference JERUSALEM , June 12, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company developing inflammation and immunology (I&I) therapies and offering biologics CDMO services through its Scinai BioServices unit, today announced CEO Amir Reichman's participation i...
Neutral
PRNewsWire
2 months ago
The regulatory approval marks a key milestone toward the potential acquisition of Pincell, removing a major condition precedent under the option agreement and allowing Scinai to advance toward finalizing the transaction, subject to customary remaining conditions. JERUSALEM , June 5, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.
More BiondVax Pharmaceuticals Ltd. Sponsored ADR News

Company Profile

BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases. It works on M-001, a synthetic peptide-based protein targeting both seasonal and pandemic strains of the influenza virus. The company was founded by Ron Babecoff and Rami Epstein on July 22, 2003 and is headquartered in Jerusalem, Israel.

Head office Israel
CEO Amir Reichman
Employees 31
Founded 2003
Website www.scinai.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today